OTC: IPHYF - Innate Pharma S.A.

六个月盈利: +16.47%
部门: Healthcare

促销时间表 Innate Pharma S.A.


关于公司

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally.

更多详情
The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

ISIN FR0010331421
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.innate-pharma.com
每日价格变化: 0% (2.9)
每周价格变化: 0% (2.9)
每月价格变化: +126.56% (1.28)
3个月内价格变化: +29.18% (2.245)
六个月内的价格变化: +16.47% (2.49)
每年价格变化: +2.11% (2.84)
3年内价格变化: -41% (4.915)
5年内价格变化: -61.33% (7.5)
10年价格变化: 0% (2.9)
年初以来价格变化: +114.81% (1.35)

低估

姓名 意义 年级
P/S 3.87 4
P/BV 4.28 4
P/E 0 0
EV/EBITDA -9.96 0
全部的: 4.75

效率

姓名 意义 年级
ROA, % -4.56 0
ROE, % -16.19 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -2.06 10
全部的: 9.4

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -18.41 0
盈利能力 Ebitda, % -77.91 0
盈利能力 EPS, % -67.14 0
全部的: 0.8



导师 职称 支付 出生年份
Mr. Yannis Morel Ph.D. Executive VP, COO & Member of Executive Board 391.92k 1973 (52 年)
Dr. François Romagné Ph.D. Founder N/A 1964 (61 年)
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. Founder, Senior VP & Chief Scientific Officer N/A 1964 (61 年)
Dr. Marc Bonneville Ph.D. Founder N/A 1960 (65 年)
Mr. Jean Jacques Fournié Ph.D. Founder N/A
Mr. Alessandro Moretta M.D., Ph.D. Founder N/A
Mr. Frederic Lombard M.B.A. Senior VP & CFO N/A 1975 (50 年)
Dr. Herve Brailly Ph.D. Co-Founder, Interim CEO & Chairman of Executive Board N/A 1961 (64 年)
Dr. Sonia Quaratino M.D., Ph.D. Executive VP, Chief Medical Officer & Member of Executive Board N/A 1967 (58 年)
Mr. Arvind Sood Executive VP, President of US Operations & Member of Executive Board N/A

地址: France, Marseille, 117. Avenue de Luminy - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.innate-pharma.com